Pre-clinical stody of subchronic toxicity of ormustine in dogs

Introduction. In N. N. Blokhin National Medical Research Center of Oncology were made preclinical toxicological studies of drmustine, a new antitumor drug from the class of nitrosoureas. The paper presents some results of study the subchronic toxicity ofdrmustine in dogs. Objective. The objective of the present study was to investigate the subchronic toxicity of оrmustine on dogs with a daily intravenous administration during 3 days.

Materials and methods. The study was performed in 12 dogs of the English beagle breed of males and females. Ormustine was adminis¬tered intravenously daily during 3 days in total doses of 1, 5, 10, 20 and 30 mg/kg. During the experiment, to study the damaging effect of ormustin on organs and tissues, clinical and lab tests andpathomorphological examinations were performed.

Results. Ormustin in doses of 20 and 30 mg/kg caused the death of animals on the 7th and 8th day of observation against the background of severe hemato-and gastrointestinal toxicity. In dogs receiving the drug in all doses, there were external manifestations of intoxication and changes in behavioral reactions, weight loss during the entire observation period. It was found that the drug had a dose-related myelosuppressive effect. Ormustin caused pronounced morphological changes of varying degrees of reversibility in the small intestine, kidneys, thyroid gland, liver, lymph nodes, spleen, heart and gonads; less pronounced — in the large intestine, stomach and bladder. Conclusion. According to the study, the total doses of ormustin 20 and 30 mg/kg were characterized as lethal, 5 and 10 mg/kg — high toxic, 1 mg/kg — low toxic dose.

1. Zaridze D.G., Kaprin A.D., Stilidi I.S. Dynamics of morbidity and mortality from malignant tumors in Russia. Voprosy onkologii = Oncology issues 2018;64(5):578—91. (In Russ.).

2. Volkova A.R., Vakhitov Kh. M., Kumirova E.V et al. Primary malignant neoplasms of cerebrospinal nervous system in children: perspectives of improvement of diagnostic and treatment approaches. Tikhookeanskiy meditsinskiy zhurnal = Pacific Medical Journal 2019;76(2):8—10. (In Russ.).

3. Kobyakov G.L., Bekyashev A.Kh., Golanov A.V et al. Practical recommendations for the medicinal treatment of primary tumors of the central nervous system. Malignant tumors: Practical recommendations RUSSCO 2018;8(3s2):83—99. (In Russ.).

4. Stroyakovsky D.L., Abramov M.E., Demidov L.V et al. Practical recommendations for the medicinal treatment of skin melanoma. Malignant tumors: Practical recommendations RUSSCO 2018;8(3с2):213—26. (In Russ.).

5. Krasnov V.P., Levit G.L., Matveeva T.V. et al. N5-nitroso-N5-[(2-chloroethyl)carbamoyl]-L-ornithine. Patent of the Russian Federation № 2503657, 10.01.2014. (In Russ.).

6. Nikolaeva L., Oborotova N., Bunyatyan N. et al. The development of a parenteral pharmaceutical formulation of a new class of compounds of nitrosourea. Pharmaceuticals 2016;9(4):68. DOI: 10.3390/ph9040068.

7. Smirnova G.B., Borisova Yu.A., Kalishyan M.S. et al. Comparative study of a new nitrosated derivatives ormustine with mustophoran on subcutaneous xenografts of human melanoma Mel7. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(1):132—3. (In Russ.).

8. Smirnova Z.S., Borisova L.M., Kiseleva M.P. et al. Antitumor efficacy of ormustine, a new drug class nitrosoalkylurea, against transplantable tumors of mice. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(1):133. (In Russ.).

9. Отчетные материалы Научного совета РАН по органической химии за 2015 год. М., 2016. Доступно по: http://zioc.ru/files/Dostigenija%202015%20-%20to%20print.pdf.

10. Chaley V.A., Konyaeva O.I., Ermakova N.P. et al. Preclinical toxicity study of a new antineoplastic drug Ormustine in small laboratory animals. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2015;14(4):65—72. (In Russ.).

11. Chaley V.A., Konyaeva O.I., Ermakova N.P. et al. Pre-clinical study of subchronic toxicity of Ormustine on rats. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2018;17(4):98—105. (In Russ.).

12. Methodological instructions for studying the general toxic effects of antitumor drugs. In: Guideto experimental (preclinical) study of new pharmacological substances. Ed.: R.U. Khabriev, Мoscow: Medicine, 2005. P. 170—204. (In Russ.).

13. Gus’kova T.A. Toxicology of medicines. 2nd edn. ed. Мoscow: MDV, 2008. 196 p. (In Russ.).